Clinical Trials Directory

Trials / Unknown

UnknownNCT04462185

A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers

Status
Unknown
Phase
Study type
Observational
Enrollment
3,000 (estimated)
Sponsor
AnchorDx Medical Co., Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The broad goals of this study is to identify changes in genomic landscape during transition from stage 0 to stage 1 lung cancer. This study intends to determine whether diagnostic biomarkers measured in minimally invasive biospecimens are able to correlate molecular, clinical and imaging features to distinguish malignant from benign pulmonary nodules. The diagnostic markers once validated can be used as broad screening tools for lung cancer.

Detailed description

The four-year study aims to recruit 3000 patients (1500 GGO and 1500 solid / semi solid nodules) in the study based on qualifying for a lung cancer screening CT or by routine CT chest with the observation of a lung nodule between 5-30mm diameter. These patients will be followed for 2\~3 years and be managed according to institutional standard of care. This may involve the Chinese Thoracic Society guideline or Fleischner criteria (either 2013 or 2017 guidelines). The clinical data, CT imaging and biospecimens will be collected during each visit. Once a patient undergoes surgery, tissue samples (FFPE) from surgery will also be collected. The gold standard for lung cancer diagnosis will be the results of bronchoscopic biopsy of lung or lymph nodes, percutaneous biopsy of lung or other organ sites, surgical biopsy or resection, or a minimum follow-up of 2 years.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTA genomic and transcriptomic landscape analysisA genomic and transcriptomic landscape analysis will be developed to identify and characterize the transcriptome of benign versus malignant by using RNA sequencing, and to profile cfDNA in blood samples collected from patients with pulmonary nodules.

Timeline

Start date
2020-07-01
Primary completion
2024-06-01
Completion
2024-12-01
First posted
2020-07-08
Last updated
2023-05-24

Locations

6 sites across 1 country: China

Source: ClinicalTrials.gov record NCT04462185. Inclusion in this directory is not an endorsement.